Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salvia miltiorrhiza + ligustrazine injection
- Development stage
- Unknown
- Lead developer
- Harbin Yuheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Salvia miltiorrhiza ligustrazine injection is a Chinese patent medicine (CPM) combination therapy primarily used in China for the treatment of cardiovascular and cerebrovascular diseases, such as chronic stable angina pectoris and ischemic stroke. It combines the extracts of *Salvia miltiorrhiza* (Danshen), which contains active components like salvianolic acids and tanshinones, with ligustrazine (tetramethylpyrazine), an alkaloid derived from *Ligusticum chuanxiong*. The mechanism of action involves the inhibition of platelet aggregation, vasodilation of coronary and peripheral arteries, and reduction of inflammatory cytokines. It is typically administered via intravenous infusion and is marketed by several Chinese pharmaceutical companies, including Harbin Gloria Pharmaceuticals. Clinical evaluations, including Phase 4 trials, have explored its effects on inflammatory markers and gut microbiota in patients with coronary heart disease.
- Brand names
- Danshen Chuanxiongqin
- Other names
- Salvia miltiorrhiza and ligustrazine hydrochloride injectionDanshen Chuanxiongqin Zhusheyesalvia miltiorrhiza ligustrazine injection
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on salvia miltiorrhiza + ligustrazine injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salvia miltiorrhiza + ligustrazine injection.